Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ainara Soria Rivas
Observed names:
A Soria Rivas,
A. Soria Rivas,
AINARA SORIA RIVAS,
Ainara Soria
Institution:
Hospital Universitario Ramón y Cajal
Observed institutions:
Hospital Universitario La Paz,
Instituto Ramón y Cajal de Investigación Sanitaria,
Hospital Universitario Ramón y Cajal
ORCID:
0000-0002-4673-8989
Observed ORCID:
0000-0002-4673-8989
OpenAlex ID:
A5030027396
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
2024
·
Jean-Pascal Machiels
, Yungan Tao
, et al.
·
The Lancet Oncology
·
297
SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023)
2024
·
Ainara Soria Rivas
, Yolanda Escobar Álvarez
, et al.
·
Clinical & Translational Oncology
·
33
Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments
2022
·
Alfonso Cortés
, José L. Casado
, et al.
·
European Journal of Cancer
·
28
PDF
sVEGFR2 and circulating tumor cells to predict for the efficacy of pazopanib in neuroendocrine tumors (NETs): PAZONET subgroup analysis.
2013
·
Enrique Grande
, Oriol Casanovas
, et al.
·
Journal of Clinical Oncology
·
14
Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma
2025
·
Eva Munoz-Couselo
, Ainara Soria Rivas
, et al.
·
Cancer Research Communications
·
10
PDF
Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti–programmed death-1 therapy
2022
·
Shahneen Sandhu
, Victoria Atkinson
, et al.
·
European Journal of Cancer
·
9
PDF
LBA35 Primary results from TACTI-003: A randomized phase IIb trial comparing eftilagimod alpha (soluble LAG-3) plus pembrolizumab versus pembrolizumab alone in first-line recurrent or metastatic head and neck squamous cell carcinoma with CPS ≥1
2024
·
C.A. Kristensen
, R. Metcalf
, et al.
·
Annals of Oncology
·
8
Treatment of metastatic squamous cell carcinoma arising in sacrococcygeal pilonidal sinus: a case report series
2023
·
Ainara Soria Rivas
, Sonia Bea-Ardebol
, et al.
·
Frontiers in Medicine
·
6
A randomized phase 2 trial of the IO102-IO103 (IDO and PD-L1) cancer vaccine plus pembrolizumab as neoadjuvant/adjuvant treatment of patients with solid tumors.
2024
·
Georgina V. Long
, Robert I. Haddad
, et al.
·
Journal of Clinical Oncology
·
5
PDF
Temozolamide plus capecitabine as salvage treatment for patients with advanced neuroendocrine tumors (NETs) in the community setting.
2013
·
Carlos López-López
, Paula Jiménez
, et al.
·
Journal of Clinical Oncology
·
4
1022P A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: Completed cohort for first-line (1L) treatment of advanced squamous cell carcinoma of the head and neck (SCCHN)
2024
·
J.W. Riess
, J. Spicer
, et al.
·
Annals of Oncology
·
3
Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: Results from the observational study GEM1801.
2023
·
Pablo Ayala de Miguel
, Miguel-Angel Berciano-Guerrero
, et al.
·
Journal of Clinical Oncology
·
3
Interim analysis of a phase Ib study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild type melanoma progressing on prior anti-PD-L1 therapy
2019
·
S.K. Sandhu
, V.G. Atkinson
, et al.
·
Annals of Oncology
·
3
Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registry
2025
·
Maria Gonzalez-Cao
, Miguel-Ángel Berciano-Guerrero
, et al.
·
Clinical & Translational Oncology
·
2
Recommendations for the management of cutaneous squamous cell carcinoma: a systematic multidisciplinary Delphi consensus approach
2024
·
Eva Muñoz Couselo
, Javier Cañueto
, et al.
·
Clinical & Translational Oncology
·
2
VP5-2024: Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study
2024
·
R. Metcalf
, S. Laban
, et al.
·
Annals of Oncology
·
2
PDF
675 TACTI-003: A randomized phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma
2022
·
Irene Brana
, Valerii Cheshuk
, et al.
·
Journal for ImmunoTherapy of Cancer
·
2
PDF
Remisión completa de enfermedad de Crohn tras tratamiento con megadosis de interferón alfa por un melanoma maligno
2015
·
Carlos Ferre Aracil
, Enrique Rodríguez de Santiago
, et al.
·
Gastroenterología y Hepatología
·
2
Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial
2026
·
Hye Ryun Kim
, Marc Oliva
, et al.
·
European Journal of Cancer
·
1
Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801
2025
·
Enrique Espinosa
, Miguel-Ángel Berciano-Guerrero
, et al.
·
Clinical & Translational Oncology
·
1
PDF
56P Efficacy and safety of nivolumab (Nivo) in recurrent and/or metastatic platinum-refractory squamous cell carcinoma of head and neck (R/M SCCHN): A real-world data study
2020
·
J.J. Soto Castillo
, J. Esteban Villarrubia
, et al.
·
Annals of Oncology
·
1
Complete remission of Crohn's disease after high-dose alpha-interferon treatment for malignant melanoma
2016
·
Carlos Ferre Aracil
, Enrique Rodríguez de Santiago
, et al.
·
Gastroenterología y Hepatología (English Edition)
·
1
1646P Efficiency of second-line BRAF/MEK inhibitors in BRAFV600 mutated metastatic melanoma patients after first-line immunotherapy failure: A EUMelaReg real-world study
2025
·
E. Ellebaek
, M. Weichenthal
, et al.
·
Annals of Oncology
Skin Cancer Prevention Communication: A Global Bibliometric Analysis of the Literature from 2011 to 2021
2025
·
Ana Cristina García
, Ángeles Moreno
, et al.
·
Review of Communication Research
PDF
Data from Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma
2025
·
Eva Munoz-Couselo
, Ainara Soria Rivas
, et al.
Show more works
View as search
Works count:
48
Citation count:
437
H-index:
7
I10-index:
5
Year
Topic
Type